urea has been researched along with Chronic Hepatitis C in 9 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Adverse events (AEs) were found in less than one half of patients (45 patients, or 42." | 6.90 | [Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C]. ( Batskikh, SN; Burnevich, EZ; Chulanov, VP; Gusev, DA; Kizlo, SN; Klimova, EA; Krasavina, EN; Mamonova, NA; Samsonov, MY; Tarkhova, EP; Yushchuk, ND; Znoyko, OO, 2019) |
| "Narlaprevir (SCH 900518) is a potent inhibitor of the hepatitis C virus (HCV) nonstructural protein 3 serine protease that is primarily metabolized by the cytochrome P450-3A4 system." | 6.75 | Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients. ( Bergmann, JF; de Bruijne, J; de Knegt, RJ; Hughes, EA; Janssen, HL; Li, J; Molenkamp, R; Reesink, HW; Schinkel, J; Tong, X; Treitel, MA; van Lier, JJ; van Vliet, AA; Weegink, CJ, 2010) |
| "Achievement of a sustained virologic response (SVR) after peginterferon (PEG-IFN) and ribavirin (RBV) treatment is considered to be a marker for the cure of chronic hepatitis C virus (HCV) infection." | 5.17 | Sustained virologic response after therapy with the HCV protease inhibitor narlaprevir in combination with peginterferon and ribavirin is durable through long-term follow-up. ( Boonstra, A; de Bruijne, J; de Knegt, RJ; Hotho, DM; Janssen, HL; Reesink, HW; Spaan, M; Treitel, MA, 2013) |
| " Adverse events (AEs) were found in less than one half of patients (45 patients, or 42." | 2.90 | [Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C]. ( Batskikh, SN; Burnevich, EZ; Chulanov, VP; Gusev, DA; Kizlo, SN; Klimova, EA; Krasavina, EN; Mamonova, NA; Samsonov, MY; Tarkhova, EP; Yushchuk, ND; Znoyko, OO, 2019) |
| "Narlaprevir retreatment resulted in a 2." | 2.78 | Evolutionary dynamics of hepatitis C virus NS3 protease domain during and following treatment with narlaprevir, a potent NS3 protease inhibitor. ( Bergmann, JF; de Bruijne, J; de Knegt, RJ; Hughes, E; Janssen, HL; Molenkamp, R; Rebers, SP; Reesink, HW; Schinkel, J; Thomas, XV; Treitel, MA; Weegink, CJ, 2013) |
| "Narlaprevir (SCH 900518) is a potent inhibitor of the hepatitis C virus (HCV) nonstructural protein 3 serine protease that is primarily metabolized by the cytochrome P450-3A4 system." | 2.75 | Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients. ( Bergmann, JF; de Bruijne, J; de Knegt, RJ; Hughes, EA; Janssen, HL; Li, J; Molenkamp, R; Reesink, HW; Schinkel, J; Tong, X; Treitel, MA; van Lier, JJ; van Vliet, AA; Weegink, CJ, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Klimova, EA | 1 |
| Burnevich, EZ | 1 |
| Chulanov, VP | 1 |
| Gusev, DA | 1 |
| Znoyko, OO | 1 |
| Batskikh, SN | 1 |
| Kizlo, SN | 1 |
| Mamonova, NA | 1 |
| Tarkhova, EP | 1 |
| Krasavina, EN | 1 |
| Samsonov, MY | 1 |
| Yushchuk, ND | 1 |
| El-Sheikh, RM | 1 |
| Mansy, SS | 1 |
| Nessim, IG | 1 |
| Hosni, HN | 1 |
| El Hindawi, A | 1 |
| Hassanein, MH | 1 |
| AbdelFattah, AS | 1 |
| Hotho, DM | 1 |
| de Bruijne, J | 3 |
| Spaan, M | 1 |
| Treitel, MA | 3 |
| Boonstra, A | 1 |
| de Knegt, RJ | 3 |
| Janssen, HL | 3 |
| Reesink, HW | 3 |
| Thomas, XV | 1 |
| Rebers, SP | 1 |
| Weegink, CJ | 2 |
| Hughes, E | 1 |
| Bergmann, JF | 2 |
| Molenkamp, R | 2 |
| Schinkel, J | 2 |
| Lapiński, TW | 2 |
| Rogalska-Płońska, M | 1 |
| Czajkowska, J | 2 |
| Flisiak, R | 2 |
| Parfieniuk, A | 1 |
| Rogalska-Plonska, M | 1 |
| Tong, X | 1 |
| Li, J | 1 |
| Hughes, EA | 1 |
| van Lier, JJ | 1 |
| van Vliet, AA | 1 |
| Klimashevskaya, S | 1 |
| Obriadina, A | 1 |
| Ulanova, T | 1 |
| Bochkova, G | 1 |
| Burkov, A | 1 |
| Araujo, A | 1 |
| Stramer, SL | 1 |
| Tobler, LH | 1 |
| Busch, MP | 1 |
| Fields, HA | 1 |
| Fahim, FA | 1 |
| Esmat, AY | 1 |
| Hassan, GK | 1 |
| Abdel-Bary, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SCH 900518 in Naive or Treatment-Experienced Subjects Infected With Hepatitis C Virus Genotype 1 (Protocol No. P04695)[NCT01081158] | Phase 1 | 41 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 trials available for urea and Chronic Hepatitis C
| Article | Year |
|---|---|
[Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C].
Topics: Adult; Antiviral Agents; Carbamates; Cyclopropanes; Dipeptides; Drug Therapy, Combination; Female; G | 2019 |
Sustained virologic response after therapy with the HCV protease inhibitor narlaprevir in combination with peginterferon and ribavirin is durable through long-term follow-up.
Topics: Adult; Aged; Antiviral Agents; Cyclopropanes; Dipeptides; Double-Blind Method; Drug Therapy, Combina | 2013 |
Evolutionary dynamics of hepatitis C virus NS3 protease domain during and following treatment with narlaprevir, a potent NS3 protease inhibitor.
Topics: Adult; Antiviral Agents; Cyclopropanes; Dipeptides; Drug Therapy, Combination; Evolution, Molecular; | 2013 |
Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients.
Topics: Adult; Aged; Antiviral Agents; Cyclopropanes; Dipeptides; Drug Administration Schedule; Drug Therapy | 2010 |
5 other studies available for urea and Chronic Hepatitis C
| Article | Year |
|---|---|
Carbamoyl phosphate synthetase 1 (CPS1) as a prognostic marker in chronic hepatitis C infection.
Topics: Adult; Aged; Biomarkers; Carbamoyl-Phosphate Synthase (Ammonia); Female; Hepatitis C, Chronic; Human | 2019 |
[Influence of cryoglobulinaemia on renal function in patients with chronic HCV infection].
Topics: Adult; Biomarkers; Case-Control Studies; Creatinine; Cryoglobulinemia; Cryoglobulins; Cystatin C; Fe | 2009 |
Prevalence of cryoglobulinaemia in hepatitis C virus- and hepatitis C virus/human immunodeficiency virus-infected individuals: implications for renal function.
Topics: Adult; Creatinine; Cryoglobulinemia; Cryoglobulins; Cystatin C; Early Diagnosis; Female; Glomerular | 2009 |
Distinguishing acute from chronic and resolved hepatitis C virus (HCV) infections by measurement of anti-HCV immunoglobulin G avidity index.
Topics: Acute Disease; Antibody Affinity; Diagnosis, Differential; Enzyme-Linked Immunosorbent Assay; Hepati | 2007 |
Biochemical changes in patients with combined chronic schistosomiasis and viral hepatitis C infections.
Topics: Adult; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Bilirubin; Biomarker | 2000 |